0000000000210545

AUTHOR

Andrew J.s. Coats

showing 12 related works from this author

Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins.

2005

Background Endotoxin [lipopolysaccharide (LPS)] may be an important stimulus for cytokine release in patients with chronic heart failure (CHF). We sought to investigate the relationship between whole blood endotoxin responsiveness and serum lipoprotein concentrations. It is not known if low-dose LPS is sufficient to stimulate immune activation. Methods and results Whole blood from 32 CHF patients (mean age 66±2 years, NYHA class 2.7±0.2, five female) and 11 healthy control subjects (mean age 47±4 years, six female) was stimulated with LPS at nine different concentrations (0.001 to 10 ng/mL), and tumor necrosis factor (TNF-α) release was quantified. Reference standard endotoxin at concentrat…

LipopolysaccharidesMalemedicine.medical_specialtyLipopolysaccharidemedicine.medical_treatmentLipoproteinsEnzyme-Linked Immunosorbent Assaychemistry.chemical_compoundIn vivoInternal medicinemedicineHumansWhole bloodAgedHeart Failurebusiness.industryTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseEndocrinologyCytokinechemistryHeart failureTumor necrosis factor alphaFemaleCardiology and Cardiovascular MedicinebusinessEx vivoLipoproteinEuropean journal of heart failure
researchProduct

Exercise hyperventilation in chronic heart failure is not caused by systemic lactic acidosis

2005

Background: Patients with heart failure have an abnormally high ventilatory response to exercise associated with gas exchange defects and reduced arterial pCO2. Aims: We examined the possibility of lactic acidosis as the stimulus to this increased ventilation that abnormally depresses pCO2 during exercise in heart failure. Method and results: We studied 18 patients with chronic heart failure. We measured VE/VCO2 slope during exercise, arterial blood gases and lactate concentrations during cardiopulmonary exercise testing (rest, peak exercise and one minute after the end of exercise). Neither VE/VCO2 slope nor arterial pCO2 were related to arterial lactate concentrations at peak exercise (r=…

Malemedicine.medical_specialtypCO2Internal medicineHyperventilationmedicineHumansHyperventilationArterial pCO2AcidosisHeart FailureExercise Tolerancebusiness.industryMiddle AgedHydrogen-Ion Concentrationsmedicine.diseaseHeart failureLactic acidosisExercise TestCardiologyPhysical therapyArterial bloodAcidosis LacticFemaleBlood Gas Analysismedicine.symptomCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyEuropean Journal of Heart Failure
researchProduct

Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure.

2002

Bacterial endotoxin activity is elevated in patients with decompensated chronic heart failure (HF) and acts as a potent stimulus for immune activation. We sought to determine whether endotoxin, at an activity level seen in vivo (around 0.6 EU/ml), is sufficient to stimulate the secretion of tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha soluble receptor (sTNFR2) in ex vivo whole blood from patients with HF. We studied 15 patients with HF (aged 65 +/- 1.9 years, New York Heart Association class 2.1 +/- 0.3, left ventricular ejection fraction 31 +/- 5%; mean +/- SEM), of whom 5 had cardiac cachexia, and 7 healthy control subjects (59 +/- 5 years, p = NS). Reference endotoxin was added …

AdultMalemedicine.medical_specialtyCachexiaEnzyme-Linked Immunosorbent AssayReceptors Tumor Necrosis FactorCachexiaIn vivoInternal medicinemedicineHumansWhole bloodAgedHeart FailureEjection fractionbusiness.industryTumor Necrosis Factor-alphaVenous bloodMiddle Agedmedicine.diseaseEndotoxinsEndocrinologyHeart failureTumor necrosis factor alphaFemaleCardiology and Cardiovascular MedicinebusinessEx vivoThe American journal of cardiology
researchProduct

Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-E…

2021

Background: Retrospective analyses of clinical trials indicate that elevated serum uric acid (sUA) predicts poor outcome in heart failure (HF). Uric acid can contribute to inflammation and microvascular dysfunction, which may differently affect different left ventricular ejection fraction (LVEF) phenotypes. However, role of sUA across LVEF phenotypes is unknown. Objectives: We investigated sUA association with outcome in a prospective cohort of HF patients stratified according to LVEF. Methods: Through the Heart Failure Long-Term Registry of the European Society of Cardiology (ESC-EORP-HFLT), 4,438 outpatients were identified and classified into: reduced (= 50% HFpEF) LVEF. Endpoints were t…

medicine.medical_specialtyHeart failure030204 cardiovascular system & hematologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineInternal MedicinemedicineHumansIn patient030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyRetrospective StudiesInflammationEjection fractionbusiness.industryStroke Volumemedicine.diseasePrognosisClinical trialPhenotypechemistryQuartileHeart failureCohortCardiologyUric acidbusinessUric acid
researchProduct

Differential contribution of dead space ventilation and low arterial pCO2 to exercise hyperpnea in patients with chronic heart failure secondary to i…

2003

In chronic heart failure (CHF), the abnormally large ventilatory response to exercise (VE/VCO(2) slope) has 2 conceptual elements: the requirement of restraining arterial partial pressure of carbon dioxide (pCO(2)) from increasing (because of an increased ratio between increased physiologic dead space and tidal volume [VD/VT]) and the depression of arterial pCO(2) by further increased ventilation, which necessarily implies an important non-carbon dioxide stimulus to ventilation. We aimed to assess the contribution of these 2 factors in determining the elevated VE/VCO(2) slope in CHF. Thirty patients with CHF underwent cardiopulmonary exercise testing (age 65 +/- 11 years, left ventricular e…

Cardiomyopathy DilatedMalemedicine.medical_specialtyPartial PressureMyocardial IschemiaHyperpneaHypercapniaInternal medicineIdiopathic dilated cardiomyopathymedicineHumansTidal volumeAgedEjection fractionbusiness.industryVO2 maxRespiratory Dead SpaceCarbon DioxideMiddle Agedmedicine.diseasePulmonary AlveoliHeart failureExercise TestCardiologyBreathingFemaleAcidosis RespiratoryBlood Gas Analysismedicine.symptomPulmonary VentilationCardiology and Cardiovascular Medicinebusinesshuman activitiesHypercapniaThe American Journal of Cardiology
researchProduct

Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee o…

2020

The aims of this paper were to provide an overview of available activity monitors used in research in patients with heart failure and to identify the key criteria in the selection of the most appropriate activity monitor for collecting, reporting, and analysing physical activity in heart failure research. This study was conducted in three parts. First, the literature was systematically reviewed to identify physical activity concepts and activity monitors used in heart failure research. Second, an additional scoping literature search for validation of these activity monitors was conducted. Third, the most appropriate criteria in the selection of activity monitors were identified. Nine activi…

medicine.medical_specialtyCardiologyPhysical activity610 Medicine & healthHeart failureFitness Trackers030204 cardiovascular system & hematologyMedical and Health Sciences2705 Cardiology and Cardiovascular MedicineExercise Capacity03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansCardiac and Cardiovascular SystemsIn patientExercise physiologyAssociation (psychology)Set (psychology)ExerciseMonitoring PhysiologicHeart FailureKardiologiPhysical activitybusiness.industryPhysical activity; Activity monitor; Motion sensor; Accelerometer; Heart failuremedicine.diseaseActivity monitor[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAccelerometerHeart failure10209 Clinic for CardiologyMotion sensorPosition paperPosition PaperHuman medicineClinical MedicineCardiology and Cardiovascular MedicineRaw databusinessEuropean Journal of Heart Failure
researchProduct

Treatment of Chronic Congestive Heart Failure

1992

medicine.medical_specialtyChronic congestive heart failurebusiness.industryInternal medicineCardiologyMedicineGeneral MedicinebusinessNew England Journal of Medicine
researchProduct

The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure…

2021

n/a Funding Agencies|Applied Therapeutics; Innolife; Novartis PharmaceuticalsNovartis; Abbott DiagnosticsAbbott Laboratories; AstraZenecaAstraZeneca; AbbottAbbott Laboratories; Boehringer IngelheimBoehringer Ingelheim; Cardior Pharmaceuticals Gmbh; Ionis Pharmaceuticals, Inc.; Novo NordiskNovo Nordisk; RocheRoche Holding; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Swiss Heart Foundation; KTI; European UnionEuropean Commission; University of Basel; University Hospital Basel; Beckman Coulter; BRAHMS; Idorsia; NovartisNovartis; Ortho Clinical Diagnostics; Quidel; SiemensSiemens AG; Singulex; Sphingotec; CardioRenal

medicine.medical_specialtyNT-PROBNPMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemNatriuretic Peptide BrainmedicineMANAGEMENTHumansCardiac and Cardiovascular Systems030212 general & internal medicineNatriuretic PeptidesIntensive care medicineDYSPNEAHeart FailureKardiologibusiness.industryEmergency departmentASSOCIATIONmedicine.diseasePeptide FragmentsEMERGENCY-DEPARTMENT3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEuropeAction (philosophy)Heart failurePeptidesCardiology and Cardiovascular MedicinebusinessAtrial Natriuretic FactorBiomarkers
researchProduct

Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival

2004

Heat shock protein 70 (Hsp70) is essential for cellular recovery, survival and maintenance of cellular function. Research into the possible use of Hsp70 as a cytoprotective therapeutic agent is ongoing. Chronic heart failure (CHF) is a state associated with systemic inflammation, particularly in patients with cardiac cachexia. We hypothesised that circulating Hsp70 levels are elevated in patients with CHF, more so in cachechtic patients, and that Hsp70 levels would relate to mortality.We studied 107 patients (28 female, age 67+/-1 years, NYHA class 2.6+/-0.6 and LVEF 29+/-1%, mean+/-SEM) and 21 controls. Cardiac cachexia was present in 32 patients. Hsp70 was detectable in 41% of CHF patient…

Malemedicine.medical_specialtyCachexiaSystemic inflammationSeverity of Illness IndexCachexiaDisease severityInternal medicineHumansMedicineHSP70 Heat-Shock ProteinsIn patientcardiovascular diseasesAgedHeart FailureEjection fractionProportional hazards modelbusiness.industryMiddle Agedmedicine.diseaseHsp70Survival RateEndocrinologyCase-Control StudiesHeart failureChronic Diseasecardiovascular systemCardiologyCytokinesFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

The relationship between age and production of tumour necrosis factor-α in healthy volunteers and patients with chronic heart failure

2003

Ageing is associated with an altered immune response. Elevated plasma levels of tumour necrosis factor-alpha (TNF-alpha) are present in patients with advanced chronic heart failure (CHF). However, the relationship between age and the immune response in CHF is unknown.We investigated the relationship between age and the TNF-alpha generating capacity of lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in nine healthy control subjects (mean age 51.6+/-3.6 years, age range 39-75 years) and 22 stable patients with CHF (mean age 68.3+/-1.5 years, age range 52-78 years, NYHA class 3.0+/-0.2). We also tested the TNF-alpha generating capacity of all control subjects and …

AdultLipopolysaccharidesMalemedicine.medical_specialtyHeart diseaseEnzyme-Linked Immunosorbent AssayPeripheral blood mononuclear cellMonocytesImmune systemInternal medicinemedicineHumansAgedWhole bloodHeart FailureAnalysis of VarianceTumor Necrosis Factor-alphabusiness.industryAge FactorsGestational ageMiddle Agedmedicine.diseaseLogistic ModelsEndocrinologyAgeingCase-Control StudiesHeart failureChronic DiseaseImmunologyFemaleTumor necrosis factor alphaCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct

Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology

2020

Self-care is essential in the long-term management of chronic heart failure. Heart failure guidelines stress the importance of patient education on treatment adherence, lifestyle changes, symptom monitoring and adequate response to possible deterioration. Self-care is related to medical and person-centred outcomes in patients with heart failure such as better quality of life as well as lower mortality and readmission rates. Although guidelines give general direction for self-care advice, health care professionals working with patients with heart failure need more specific recommendations. The aim of the management recommendations in this paper is to provide practical advice for health profe…

medicine.medical_specialty2013 ACCF/AHA GUIDELINElifestyleTreatment adherenceCardiologyheart failure/dk/atira/pure/subjectarea/asjc/2700/2705Heart failureNursing030204 cardiovascular system & hematologyAMERICAN-COLLEGEEXERCISE CAPACITYpatient education03 medical and health sciencesAIR-TRAVEL0302 clinical medicineQuality of life (healthcare)MEDICATIONQUALITY-OF-LIFEHealth careself-caremedicineHumansIn patientIntensive care medicineVENTRICULAR DYSFUNCTIONbusiness.industrySymptom managementOmvårdnadSelf‐careDisease ManagementPatient educationmedicine.diseaseLifestyle3. Good healthSelf CareHeart failureChronic DiseaseSelf careQuality of LifeCARDIOVASCULAR-DISEASESSelf-care; Heart failure; Lifestyle; Patient educationPosition PaperSelf-carebusinessCardiology and Cardiovascular MedicineREDUCED EJECTION FRACTIONPatient educationTASK-FORCE
researchProduct

The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure

2006

Background: Activation of the endotoxin (LPS) receptor, CD14, leads to tumor necrosis factor-alpha (TNF) production. Plasma LPS activity is elevated in patients with severe chronic heart failure (CHF). An anti-CD14 antibody, IC14, blocks TNF production in healthy volunteers. It is not known whether IC14 prevents TNF production in CHF patients. Methods and results: Blood from 20 CHF patients (age 64±2.1 years, NYHA class 2.2±0.1, LVEF 27±3%, mean±SEM) was pre-incubated with 0.5, 1.0, 5.0, 10 and 50 μg/mL IC14 for 1 h followed by incubation with 1 or 10 ng/mL LPS for 6 h. Fourteen subjects served as controls (58±2.4 years). LPS-stimulated TNF release was 76% and 60% greater at 1 and 10 ng/mL …

Malemedicine.medical_specialtyCD14Cardiac Output LowLipopolysaccharide ReceptorsInternal medicinemedicineHumansRNA MessengerReceptorAgedWhole bloodEjection fractionbiologyTumor Necrosis Factor-alphabusiness.industryMiddle AgedFlow Cytometrymedicine.diseaseEndotoxinsEndocrinologyHeart failurebiology.proteinFemaleTumor necrosis factor alphaAntibodyCardiology and Cardiovascular MedicinebusinessEx vivoEuropean Journal of Heart Failure
researchProduct